Charles Hensley, Ph.D., Inventor of Zicam(R) Cold Remedy and Itonis Pharmaceuticals to Use Its Exclusive Manufacturer for Emesyl(TM) Anti-Nausea Swab and Oral Spray Products

LAGUNA HILLS, Calif., May 3, 2013 (GLOBE NEWSWIRE) -- Itonis, Inc. (OTC:ITNS) and Charles Hensley, Ph.D., the inventor of the Zicam® Cold Remedy, and founding member of Itonis Pharmaceuticals, are pleased to announce that the Company's exclusive manufacturer (Oasis Health Products, Inc.) will produce the Company's anti-nausea swab and its oral spray products under the Emesyl™ brand.

The Company expects to commence the production process with Oasis Health Products for Emesyl™ in both the swab and oral spray forms.

Dr. Hensley said, "We are excited that we are working with Oasis to produce the first of our Emesyl™ anti-nausea products. We look forward to making Emesyl™ available to the general public to treat nausea ailments."

About Itonis Pharmaceuticals

Itonis Pharmaceuticals, a new division of Itonis, Inc., is headed by Charles Hensley, Ph.D. This division's mission is to create and market over-the-counter and prescription homeopathic products that better people's lives. Dr. Hensley is a pioneer in the development and marketing of safe and effective therapeutic nutraceutical and homeopathic preparations. He was a founder of the company that launched the Zicam® Cold Remedy, making the product a household name and forever changing the marketing and product placement paradigm for homeopathic drugs in the United States. Dr. Hensley and his team plan to use the same methodologies to revolutionize the treatment of several other common ailments and other chronic diseases.

About Itonis, Inc.

Itonis, Inc. was incorporated in the state of Nevada on July 5, 2005 under the name of Kenshou, Inc., which later changed to Itonis, Inc. on December 2, 2005. For more information, please visit

Safe Harbor:

Statements in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company's future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company's affiliates that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, seasonal changes, and other risks detailed from time to time in the Company's filings with the U.S. Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release.

CONTACT: Michael Biddick (949) 529-1588Source:Itonis Inc.